Zejing pharmaceutical: an advance loss of 372 million yuan to 455 million yuan in 2021

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Shanghai Electric Wins Malaysia’s 500MW Samalaju Project, Advancing Gas Turbine Exports

Shanghai Electric（上海电气）said on September 8 that it had won the bid for Unit 3 of the Samalaju combined-cycle gas power project in Sarawak, Malaysia. The 500MW-class unit will use a gas turbine manufactured by the Chinese group, which described the award as paving the way for its first overseas application of such equipment.

Zhipu AI’s H1 Revenue Jumps Nearly 400% as API Business Takes 86.5% of Sales

Zhipu AI（智谱）reported first-half 2026 revenue of CNY 953.9 million, up 399.7% year on year and already above its CNY 724 million full-year revenue for 2025. The result was driven by its cloud-based open platform and API business, which generated CNY 825.2 million, up 2,735.7%, and accounted for 86.5% of total revenue.

Chinese Quantum Software Startup Entropy Function Raises Angel Funding for Classical Quantum-Simulation Platform

Entropy Function（熵函数）, a Shenzhen-based quantum-computing software startup, has completed an angel round worth tens of millions of yuan led by GSR Ventures（金沙江创投）, with participation from several other investors. The company said the proceeds will fund its quantum-computing platform, hiring and services for research and industrial users.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.